Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleSmoking and Diabetes Mellitus: Results from Meta-analysis with Eight Independent Replication Samples
Author(s)Alshaarawy O, Anthony JC.
Journal, Volume, IssueEpidemiology. 2015 Jul;26(4):597-600.
Major outcome(s)Cannabis use was associated with a 30% reduction of diabetes risk
IndicationAbstract
MedicationCannabis

BACKGROUND: Pre-clinical studies link cannabinoid-1 receptor activation to inflammation and atherosclerotic effects; anti-inflammation and immunosuppression seem to be mediated by cannabinoid-2 receptor activation. In this epidemiological study, we aim to present estimates on suspected cannabis-attributable immunomodulation as manifest in serum C-reactive protein (CRP) levels as non-specific inflammatory markers with interpretable clinical values. With strength of data from recent large nationally representative community sample surveys, the research approach illustrates value of a quantile regressions approach in lieu of the commonly used but relatively arbitrary cutpoints for CRP values. METHODS: The study population encompasses 20-59 year old participants from the National Health and Nutrition Examination Surveys, 2005-2010 (n=1115 recently active cannabis smokers and 8041 non-smokers, identified via confidential Audio Computer Assisted Self-Interviews). Age, sex, race, education, income-poverty ratio, alcohol consumption, and tobacco smoking also were measured, together with body mass index (BMI), which actually might be on a mediational path. Quantile regressions, with bootstrapping for variance estimation, made it possible to hold these covariates constant while estimating cannabis-CRP associations. RESULTS: Evidence suggesting possible cannabis-attributable immunomodulation emerges at CRP levels below the median (p<0.05). Whereas BMI might help explain a cannabis link with serum CRP, but BMI-stratified analyses disclosed no appreciable variation of the cannabis-CRP relationship across BMI subgroups. CONCLUSIONS: Extending pre-clinical research on cannabis-attributable immunomodulation, this study's CRP evidence points toward possible anti-inflammatory effects of cannabis smoking. More definitive evidence can be derived by combining pre-clinical research, studies of patients, and epidemiological research approaches.

Route(s)Inhalation
Dose(s)
Duration (days)
Participants
DesignSurvey
Type of publicationMedical journal
Address of author(s)Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI 48823, United States.
Full texthttp://www.ncbi.nlm.nih.gov/pubmed/25978795

[Back to Overview]  [IACM Homepage]


up